ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

07 May 2024 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Provides Corporate Update

19 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

05 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

18 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

13 Jun 2023 11:09:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

02 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

02 May 2023 07:01:12 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

27 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

23 Feb 2023 07:00:01 By Nasdaq GlobeNewswire